RxDoctor Payments Data

Laurence Greenbaum, MD

Pediatric Nephrology · Atlanta, GANPI 1447278742

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $111,594 of the $163,657 with a category attached, or 68.2%. 15 manufacturers reported payments, led by AstraZeneca at 29.7% of the total.

$163,657in general payments, 2019–2025

Across 102 payments — averaging $1604.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$49K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$35K
  • Travere Therapeutics, Inc.$30K
  • Samsung Bioepis Co., Ltd.$7K
  • Vifor Pharma, Inc.$7K
  • Apellis Pharmaceuticals, Inc.$6K
  • plus $30K from 9 others
$1,475,441in research payments, 2019–2025

Across 153 payments — averaging $9643.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Vertex$553K
  • Genentech, Inc.$240K
  • AstraZeneca$208K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$115K
  • Apellis Pharmaceuticals, Inc.$74K
  • Aurinia Pharma U.S., Inc.$61K
  • plus $224K from 10 others

What the payments were for

  • Consulting fees$111,59468%
  • Speaking & faculty fees$7,0204%
  • Travel & lodging$43,83927%
  • Food & beverage$1,1641%
  • Education$400%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few pediatric nephrology providers in Georgiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$5,490
Medicare patients
20
Services billed
51

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProcysbiCysteamine Bitartrate44$3,672,620
CystadropsCysteamine Hcl25$231,209
CystaranCysteamine Hcl23$197,257

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Leadiant Biosciences, Inc.Cystaran$3,000$197,25723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few pediatric nephrology providers in Georgiaon file to place this against a meaningful peer group, so we don't.

Other pediatric nephrology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →